Table 4.
Risk factors for poor visual acuity at presentation in better-seeing eyes of patients with JIA-related uveitis
| Characteristic | 20/50 or worse | 20/200 or worse | ||
|---|---|---|---|---|
|
Crude OR (95% CI, P)* |
Adjusted OR (95% CI, P)† |
Crude OR (95% CI, P)* |
Adjusted OR (95% CI, P)† |
|
| Age at uveitis diagnosis | 0.97 (0.89-1.06, 0.49) | 0.93 (0.84-1.04, 0.21) | ||
| Gender (male vs female) | 1.06 (0.39-2.88, 0.91) | 1.61 (0.43-6.25, 0.47) | ||
| Race (other vs white) | 1.57 (0.86-2.88, 0.14) | 1.50 (0.78-2.88, 0.22) | ||
| Bilateral disease | 6.83 (0.82-56.6, 0.08) | No events | ||
| Duration of uveitis (years) | 5.81 (1.18-28.46, 0.03) | 2.92 (0.56-15.27, 0.20) | ||
| Persistent oligoarthritis | 1.62 (0.32-8.28, 0.56) | 0.86 (0.16-4.68, 0.86) | ||
| ANA-positive | 5.28 (0.62-45.12, 0.13) | 2.32 (0.25-21.59, 0.46) | ||
| Posterior synechiae | 3.16 (0.90-11.15, 0.07) | 6.95 (0.71-67.5, 0.09) | 2.67 (0.63-11.32, 0.18) | |
| Anterior chamber flare | 2.54 (1.30-4.98, 0.006) | 6.65 (1.62-27.3, 0.008) | 3.37 (1.46-7.77, 0.004) | 3.55 (1.18-10.7, 0.02) |
| Abnormal IOP (<5 or >21 mm Hg) | 2.59 (0.78-8.56, 0.12) | 1.84 (0.44-7.65, 0.40) | ||
| Prior hypotony | 20.67 (2.54-168, 0.005) | 16.00 (1.82-140.5, 0.01) | ||
| Prior ocular hypertension | 1.43 (0.32-6.30, 0.64) | 1.80 (0.32-10.24, 0.51) | ||
| Prior systemic corticosteroids | 4.95 (1.43-17.14, 0.01) | 9.14 (1.71-48.8, 0.01) | ||
| Prior methotrexate | 0.76 (0.15-3.92, 0.74) | 1.43 0.26-7.91, 0.68) | ||
| Prior surgery | 10.21 (2.70-38.56, 0.001) | 13.26 (1.44-122, 0.02) | 6.25 (1.39-28.2, 0.02) | 7.54 (1.74-30.7, 0.01) |
| Systemic corticosteroids at presentation | 3.05 (0.63-14.85, 0.17) | 6.10 (1.15-32.4, 0.03) | ||
| Methotrexate at presentation | 0.85 (0.16-4.45, 0.85) | 0.17 (0.01-2.08, 0.16) | 1.60 (0.29-8.94, 0.59) | |
JIA = juvenile idiopathic arthritis
*
OR = Odd ratio
†
CI = Confidence interval.